Eudaimonia Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Eudaimonia Partners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,000	Closed	-$17K	–	1475
2021 Q1	$17K	Buy	+2,000	New	+$21.1K	﹤0.01%	1008
2020 Q4	–	Sell	-2,000	Closed	-$22K	–	915
2020 Q3	$22K	Buy	+2,000	New	+$18.3K	0.01%	780

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Eudaimonia Partners's SRNE Position: Q2 2021 in Review

Eudaimonia Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 2,000 shares — an estimated $17K sold.

Eudaimonia Partners first reported a position in SRNE in Q3 2020 and held it in 2 quarters. The position peaked at $22K in Q3 2020. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

Eudaimonia Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 2,000 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $17K.
Eudaimonia Partners first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 2 quarters.
Eudaimonia Partners's Sorrento Therapeutics, Inc. position peaked at $22K in Q3 2020.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.